ArticleClinical and experimental immunology2005
Antibody to severe acute respiratory syndrome (SARS)-associated coronavirus spike protein domain 2 cross-reacts with lung epithelial cells and causes cytotoxicity.
Article in Clinical and experimental immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Prevalence of autoantibody responses in COVID-19 patients: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.Nature communications · 2020Pooled it
- Review
- Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2.Molecular immunology · 2023Review
- A review of cytokine-based pathophysiology of Long COVID symptoms.Frontiers in medicine · 2023Article
- Anti-cardiolipin IgG autoantibodies associate with circulating extracellular DNA in severe COVID-19.Scientific reports · 2022Article
- SARS-CoV-2 infection relaxes peripheral B cell tolerance.The Journal of experimental medicine · 2022Article
- [Antiphospholipid autoantibodies and Covid-19].Revue francophone des laboratoires : RFL · 2022Article
- The direct and indirect effects of bioactive compounds against coronavirus.Food frontiers · 2022Review
- The Swine IFN System in Viral Infections: Major Advances and Translational Prospects.Pathogens (Basel, Switzerland) · 2022Review
- Mechanisms of Immune Dysregulation in COVID-19 Are Different From SARS and MERS: A Perspective in Context of Kawasaki Disease and MIS-C.Frontiers in pediatrics · 2022Review
- Emerging Roles of Coronavirus in Autoimmune Diseases.Archives of medical research · 2021Review
- Untangling COVID-19 and autoimmunity: Identification of plausible targets suggests multi organ involvement.Molecular immunology · 2021Article
- Coronavirus-induced autoimmunity.Clinical immunology (Orlando, Fla.) · 2021Review
- A useful and sensitive marker in the prediction of COVID-19 and disease severity: Thiol.Free radical biology & medicine · 2021Article
- Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design.Viruses · 2021Review
- Diet and Hygiene in Modulating Autoimmunity During the Pandemic Era.Frontiers in immunology · 2021Review
- Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients.Frontiers in immunology · 2021Observational
- What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19?Autoimmunity reviews · 2020Article
- Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19.Clinical and translational science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both viral effect and immune-mediated mechanism are involved in the pathogenesis of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infection. In this study, we showed that in SARS patient sera there were autoantibodies (autoAbs) that reacted with A549 cells, the type-2 pneumocytes, and that these autoAbs were mainly IgG. The autoAbs were detectable 20 days after fever onset. Tests of non-SARS-pneumonia patients did not show the same autoAb production as in SARS patients. After sera IgG bound to A549 cells, cytotoxicity was induced. Cell cytotoxicity and the anti-epithelial cell IgG level were positively correlated. Preabsorption and binding assays indicated the existence of cross-reactive epitopes on SARS-CoV spike protein domain 2 (S2). Furthermore, treatment of A549 cells with anti-S2 Abs and IFN-gamma resulted in an increase in the adherence of human peripheral blood mononuclear cells to these epithelial cells. Taken together, we have demonstrated that the anti-S2 Abs in SARS patient sera cause cytotoxic injury as well as enhance immune cell adhesion to epithelial cells. The onset of autoimmune responses in SARS-CoV infection may be implicated in SARS pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.